PetVivo Holdings Reports Slight Revenue Increase but Significant Losses for Fiscal Year Ending March 31, 2026

PetVivo Holdings, Inc. reported its financial results for the fiscal year ending March 31, 2026, revealing a slight increase in revenue but continued significant losses. The company generated total revenues of $1.14 million, a marginal rise from $1.13 million in the previous fiscal year. This revenue primarily stemmed from sales of its lead product, Spryng®, and the recently licensed PrecisePRP product, with $886,219 attributed to distributor sales and $255,388 from veterinary clinics. Despite the revenue growth, PetVivo incurred a net loss of approximately $10.47 million, compared to a loss of $8.40 million in fiscal 2025, reflecting ongoing challenges in achieving profitability.

The company's operating expenses increased to $9.82 million from $9.05 million year-over-year, driven largely by heightened sales and marketing efforts associated with the commercialization of the PrecisePRP product. General and administrative expenses decreased slightly, while research and development costs also saw a reduction. The increase in operating loss to $9.06 million from $8.06 million was primarily due to the rise in marketing expenditures. The company’s total cost of sales also rose significantly to $386,856 from $137,677, indicating higher production costs associated with its product offerings.

Strategically, PetVivo has made notable advancements in its distribution agreements, including partnerships with Vedco and Clipper Distributing, which are expected to enhance its market reach. The company transitioned from an exclusive distribution agreement with MWI to a non-exclusive arrangement, allowing for broader sales channels. Additionally, PetVivo entered into a licensing agreement with VetStem for the PrecisePRP product, which is anticipated to contribute to future revenue streams. The company is also focused on expanding its product pipeline, which includes 17 therapeutic devices for both veterinary and human applications.

Operationally, PetVivo's workforce consisted of 22 employees as of June 29, 2026, and the company continues to rely on third-party clinical studies to validate its products. The company has conducted various clinical trials, including studies at Colorado State University, to support the efficacy of Spryng® and other products. However, the company faces significant competition in the veterinary market from established players like Zoetis and Merck, which may impact its ability to capture market share.

Looking ahead, PetVivo acknowledges the need for additional capital to sustain operations and fund its commercialization efforts. As of March 31, 2026, the company reported current assets of approximately $1.86 million, with cash and cash equivalents of $200,782. The company has expressed substantial doubt about its ability to continue as a going concern, emphasizing the importance of securing further financing to support its business objectives. PetVivo plans to continue raising capital through the sale of securities to fund its operations and product development initiatives.